We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

LDC and Boehringer Ingelheim Join Forces

News   May 11, 2016

 
LDC and Boehringer Ingelheim Join Forces
 
 
 

RELATED ARTICLES

New Class of Drugs May Reduce Cardiovascular Risk by Targeting Gut Microbes

News

Researchers at Cleveland Clinic in the United States have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.

READ MORE

Highly Effective and Selective Molecule Developed to Fight Malaria

News

A novel laboratory-synthesized molecule is a strong candidate for the development of a new antimalarial drug.

READ MORE

Drugs in Development for Cancer May Also Fight Brain Diseases

News

A class of cancer drugs called PARP inhibitors could be useful for treating and preventing brain disorders, including amyotrophic lateral sclerosis, and some forms of frontotemporal degeneration, by halting the misplacement of specific proteins that affect nerve cells, according to new research.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE